Letters by company
Anaptysbio, INC
2 letters discussing ANAB. Everything written about it on this site is on its ticker page.
- Laughing Water Capital H1 2026 Laughing Water Capital sold through takeouts of Theravance Biopharma, Avanos Medical and SECURE Waste Infrastructure, leaving cash and merger securities for new opportunities. The portfolio added AnaptysBio ahead of its licensing dispute with GSK, while retaining conviction in Liquidia, NextNav, Lifecore Biomedical and Stride despite company-specific overhangs. H1 2026 +33.6% ANAB $1.7BAVNS $1.2BGSK $105BLFCR $172M
- Greenhaven Road Capital Main Fund Q2 Greenhaven Road Capital is reducing concentration and adding catalyst-driven positions while retaining its emphasis on differentiated research. It argues that Burford’s protein litigation, Hagerty’s insurer partnerships, Cellebrite’s Genesis rollout, Lifecore’s capacity sales and Kingsway’s search-model buildout can close gaps between market expectations and business value. Q2 2026 +11.0% BUR $946MCLBT $2.9BHGTY $4.6BANAB $1.7B
